Capricor Therapeutics Inc (CAPR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Capricor Therapeutics Inc (CAPR) has a cash flow conversion efficiency ratio of -0.105x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-29.25 Million) by net assets ($278.70 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See CAPR equity to assets ratio to measure how much of total assets are equity-financed.
Capricor Therapeutics Inc - Cash Flow Conversion Efficiency Trend (1999–2025)
This chart illustrates how Capricor Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check how high is Capricor Therapeutics Inc's earnings quality to evaluate the quality of earnings relative to operating cash generation.
Capricor Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Capricor Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Crexendo Inc
NASDAQ:CXDO
|
0.028x |
|
Sociedad Comercial del Plata S.A.
BA:COME
|
0.036x |
|
Strike Energy Limited
F:RJN
|
-0.013x |
|
Afrimat
JSE:AFT
|
0.117x |
|
Kpx Holdings
KO:092230
|
0.002x |
|
AC Immune Ltd
NASDAQ:ACIU
|
-0.522x |
|
Evgo Inc
NASDAQ:EVGO
|
-0.100x |
|
Electromed Inc
NYSE MKT:ELMD
|
0.067x |
Annual Cash Flow Conversion Efficiency for Capricor Therapeutics Inc (1999–2025)
The table below shows the annual cash flow conversion efficiency of Capricor Therapeutics Inc from 1999 to 2025. For the full company profile with market capitalisation and key ratios, see Capricor Therapeutics Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $305.79 Million | $-69.81 Million | -0.228x | +16.97% |
| 2024-12-31 | $145.46 Million | $-40.00 Million | -0.275x | +75.72% |
| 2023-12-31 | $22.60 Million | $-25.60 Million | -1.133x | -371.49% |
| 2022-12-31 | $11.79 Million | $4.92 Million | 0.417x | +177.85% |
| 2021-12-31 | $31.37 Million | $-16.81 Million | -0.536x | -50.29% |
| 2020-12-31 | $28.20 Million | $-10.05 Million | -0.357x | +64.25% |
| 2019-12-31 | $6.84 Million | $-6.82 Million | -0.997x | +66.79% |
| 2018-12-31 | $4.62 Million | $-13.86 Million | -3.003x | -136.94% |
| 2017-12-31 | $11.23 Million | $-14.23 Million | -1.268x | -132.11% |
| 2016-12-31 | $-4.00 Million | $-15.80 Million | 3.947x | -62.35% |
| 2015-12-31 | $-1.03 Million | $-10.82 Million | 10.484x | +6934.47% |
| 2014-12-31 | $-6.25 Million | $958.56K | -0.153x | -101.34% |
| 2013-12-31 | $-534.88K | $-6.14 Million | 11.487x | +2671.04% |
| 2012-12-31 | $4.89 Million | $-2.19 Million | -0.447x | +92.02% |
| 2011-12-31 | $830.72K | $-4.65 Million | -5.597x | -236.57% |
| 2010-12-31 | $2.60 Million | $-4.32 Million | -1.663x | +14.43% |
| 2009-12-31 | $2.98 Million | $-5.80 Million | -1.943x | +6.78% |
| 2008-12-31 | $5.10 Million | $-10.64 Million | -2.085x | -489.82% |
| 2007-12-31 | $15.20 Million | $-5.37 Million | -0.353x | -183.02% |
| 2006-12-31 | $-130.58K | $-55.60K | 0.426x | +85.78% |
| 2005-12-31 | $-77.62K | $-17.79K | 0.229x | -13.00% |
| 2004-12-31 | $-58.76K | $-15.48K | 0.263x | -48.52% |
| 2003-12-31 | $-40.69K | $-20.82K | 0.512x | -12.35% |
| 2002-12-31 | $-24.53K | $-14.32K | 0.584x | -59.91% |
| 2001-12-31 | $-8.94K | $-13.02K | 1.456x | +152.13% |
| 2000-12-31 | $13.36K | $-37.32K | -2.793x | -291.50% |
| 1999-12-31 | $-617.00 | $-900.00 | 1.459x | -- |
About Capricor Therapeutics Inc
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treat… Read more